Literature DB >> 10878290

Applications of tacrolimus for the treatment of skin disorders.

T Assmann1, B Homey, T Ruzicka.   

Abstract

During the last decades, systemic and topical glucocorticosteroids assumed a dominant role in immunosuppressive therapy in dermatology. However, their administration is limited because of numerous adverse effects. Consequently, there is a large need for alternative non-steroidal anti-inflammatory therapeutics with a superior risk/benefit ratio. In recent years, a new class of anti-inflammatories, the macrolide lactones, has attracted special interest. During the last decade, a member of this class, tacrolimus, proved to be a powerful suppressor of the immune system. Introduced into clinical practice to prevent allograft rejection, it is now routinely used in organ transplantation. Recently, several placebo-controlled multicenter studies showed the therapeutic efficiency of systemic and topical tacrolimus in common inflammatory skin diseases such as psoriasis and atopic eczema.Short-term tacrolimus ointment therapy disclosed significant efficacy vs. placebo and a safety profile with only few local side effects in patients with atopic eczema. Further clinical trials including greater extent of exposure (experienced by children), and comparison between tacrolimus ointment and glucocorticosteroids are being conducted and the results will show whether this drug opens a new era in the treatment of inflammatory skin disorders. The aim of this review is to summarize the current knowledge regarding the pharmacokinetic properties, adverse effects and therapeutic indications of tacrolimus in dermatology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878290     DOI: 10.1016/s0162-3109(00)00187-9

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  5 in total

1.  Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis.

Authors:  C Matsuda; T Ito; J Song; T Mizushima; H Tamagawa; Y Kai; Y Hamanaka; M Inoue; T Nishida; H Matsuda; Y Sawa
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

2.  Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats.

Authors:  Gwenn E McLaughlin; Michelle Schober; Maria Perez; Phillip Ruiz; Bernard W Steele; Carolyn Abitbol
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

3.  Local application of rapamycin reduces epidural fibrosis after laminectomy via inhibiting fibroblast proliferation and prompting apoptosis.

Authors:  Yu Sun; Shuai Zhao; Xiaolei Li; Lianqi Yan; Jingcheng Wang; Daxin Wang; Hui Chen; Jihang Dai; Jun He
Journal:  J Orthop Surg Res       Date:  2016-05-06       Impact factor: 2.359

Review 4.  Management of Atopic Dermatitis: The Role of Tacrolimus.

Authors:  Badar Uddin Umar; Sayeeda Rahman; Siddhartha Dutta; Tariqul Islam; Nadia Nusrat; Kona Chowdhury; Wan Farizatul Shima Binti Wan Ahmad Fakuradzi; Mainul Haque
Journal:  Cureus       Date:  2022-08-18

5.  MicroRNA profiling of tacrolimus-stimulated Jurkat human T lympocytes.

Authors:  Ho Kyun Lee; Sang Young Chung; Soo Jin Na Choi
Journal:  J Korean Surg Soc       Date:  2013-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.